Search details
1.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell
; 175(4): 998-1013.e20, 2018 11 01.
Article
in English
| MEDLINE | ID: mdl-30388456
2.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell
; 176(1-2): 404, 2019 Jan 10.
Article
in English
| MEDLINE | ID: mdl-30633907
3.
B cells and tertiary lymphoid structures promote immunotherapy response.
Nature
; 577(7791): 549-555, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31942075
4.
Interaction of molecular alterations with immune response in melanoma.
Cancer
; 123(S11): 2130-2142, 2017 06 01.
Article
in English
| MEDLINE | ID: mdl-28543700
5.
Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy.
Curr Oncol Rep
; 18(7): 42, 2016 07.
Article
in English
| MEDLINE | ID: mdl-27215436
6.
Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity.
Front Cell Dev Biol
; 12: 1358583, 2024.
Article
in English
| MEDLINE | ID: mdl-38827528
7.
A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response.
Cell Rep Med
; 5(5): 101511, 2024 May 21.
Article
in English
| MEDLINE | ID: mdl-38614094
8.
Organoid generation from mouse mammary tumors captures the genetic heterogeneity of clinically relevant copy number alterations.
bioRxiv
; 2023 Jan 31.
Article
in English
| MEDLINE | ID: mdl-36778256
9.
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
J Immunother Cancer
; 11(5)2023 05.
Article
in English
| MEDLINE | ID: mdl-37230537
10.
Generating and Imaging Mouse and Human Epithelial Organoids from Normal and Tumor Mammary Tissue Without Passaging.
J Vis Exp
; (189)2022 11 11.
Article
in English
| MEDLINE | ID: mdl-36440890
11.
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
Cancer Immunol Res
; 10(7): 829-843, 2022 07 01.
Article
in English
| MEDLINE | ID: mdl-35561311
12.
Mast Cells: A New Frontier for Cancer Immunotherapy.
Cells
; 10(6)2021 05 21.
Article
in English
| MEDLINE | ID: mdl-34063789
13.
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers.
Genome Med
; 13(1): 70, 2021 04 26.
Article
in English
| MEDLINE | ID: mdl-33902690
14.
Considerations for treatment duration in responders to immune checkpoint inhibitors.
J Immunother Cancer
; 9(3)2021 03.
Article
in English
| MEDLINE | ID: mdl-33653801
15.
Atezolizumab for the treatment of breast cancer.
Expert Rev Anticancer Ther
; 20(3): 151-158, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32067545
16.
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.
Nat Commun
; 11(1): 1839, 2020 04 15.
Article
in English
| MEDLINE | ID: mdl-32296058
17.
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.
Cancer Immunol Res
; 7(6): 1025-1035, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31043414
18.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Nat Med
; 24(11): 1649-1654, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30297909
19.
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Nat Med
; 24(12): 1941, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30361510
20.
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
Nat Med
; 24(12): 1942, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30361511